[RHESOU (Registry in HErault Specialized in Onco-Urology) : the first French Registry specialized in Onco-Urology. One-year experience].

RHESOU (Registre de l’Hérault spécialisé en onco-urologie) : le premier registre français spécialisé en onco-urologie. Un outil méthodologique de recueil de données en onco-urologie. Bilan de faisabilité sur un an d’expérience.
Base de données Cancers génitaux masculins Cancers urologiques Cancers urologiques féminins Data collection Epidemiology Male and female urological cancers Male genital cancers Registre Registry Épidémiologie

Journal

Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie
ISSN: 1166-7087
Titre abrégé: Prog Urol
Pays: France
ID NLM: 9307844

Informations de publication

Date de publication:
Dec 2020
Historique:
received: 04 05 2020
revised: 13 08 2020
accepted: 06 09 2020
pubmed: 6 10 2020
medline: 8 7 2021
entrez: 5 10 2020
Statut: ppublish

Résumé

In 2016, the Herault tumor registry collected 1961cancers in urology (21.4 % from all Herault cancers this year). RHESOU was created to complete RTH' data with specific parameters in onco-urology. The aim of this study is to describe RHESOU and to give some examples with our first results. In November 2018, RHESOU (Registry HErault Specialised in Onco-Urology) was founded with the same registry recommendations. It collects specific oncologic parameters and also complete RTH's data. For each urological cancer, a specific survey with different choices was performed to collect a maximum of data which could be present in patients' file. These surveys were used for urological cancers cases that live in Herault in 2017. In 2017, we collected 970 prostate cancers, 581 bladder cancers, 212 kidney cancers, 51 upper excretory tract cancers, 28 testicle cancers and 9 penil cancers. Our urological data collection gives many possibilities to create many requests for detailed analysis in urological cancers. In this article, we reported data from kidney, bladder and prostate cancers. RHESOU is a new tool opened to the different urologic corporations (urologists, pathologists, oncologists, radiotherapists, radiologists) that permits an overview in urological cancers in Herault. Finally, one important aim is that this tool will be adapted when new treatments or new important parameters appear in the years ahead. 3.

Identifiants

pubmed: 33012630
pii: S1166-7087(20)30592-3
doi: 10.1016/j.purol.2020.09.015
pii:
doi:

Types de publication

Journal Article

Langues

fre

Sous-ensembles de citation

IM

Pagination

1038-1044

Informations de copyright

Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Auteurs

S G Trouche-Sabatier (SG)

Registre des tumeurs de l'Hérault, Montpellier, France. Electronic address: registre-tumeur@wanadoo.fr.

X Rebillard (X)

Comité de pilotage, Montpellier, France; Clinique Beau Soleil, Montpellier, France.

F Iborra (F)

Comité de pilotage, Montpellier, France; CHU de Montpellier, Montpellier, France.

D Azria (D)

Comité de pilotage, Montpellier, France; Inserm U 1194, ICM, université Montpellier, Montpellier, France.

J-P Daures (JP)

Comité de pilotage, Montpellier, France; Clinique Beau Soleil, Montpellier, France; IURC, Montpellier, France.

G Poinas (G)

Comité scientifique du RHESOU, Montpellier, France; Clinique Beau Soleil, Montpellier, France.

N Abdo (N)

Comité scientifique du RHESOU, Montpellier, France; CHU de Montpellier, Montpellier, France.

O Delbos (O)

Comité scientifique du RHESOU, Montpellier, France; Urodoc, Montpellier, France.

A Gevorgyan (A)

Comité scientifique du RHESOU, Montpellier, France; Polyclinique Saint-Privat Boujan sur Libron, Béziers, France.

S Marchal (S)

Comité scientifique du RHESOU, Montpellier, France; Urodoc, Montpellier, France.

R Guillon (R)

Comité scientifique du RHESOU, Montpellier, France; Clinique Beau Soleil, Montpellier, France.

I Millet (I)

Comité scientifique du RHESOU, Montpellier, France; CHU de Montpellier, Montpellier, France.

P-J Lamy (PJ)

Comité scientifique du RHESOU, Montpellier, France; Imagenome-inovie, Montpellier, France.

O Lauche (O)

Comité scientifique du RHESOU, Montpellier, France; Clinique Clémentville, Montpellier, France.

R Reis-Borges (R)

Comité scientifique du RHESOU, Montpellier, France; Inopath Labosud, Montpellier, France.

I Serre (I)

Comité scientifique du RHESOU, Montpellier, France; CHU de Montpellier, Montpellier, France.

D Topart (D)

Comité scientifique du RHESOU, Montpellier, France; CHU de Montpellier, Montpellier, France.

B Tretarre (B)

Comité de pilotage, Montpellier, France; Registre des tumeurs de l'Hérault, Montpellier, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH